240 related articles for article (PubMed ID: 23921424)
1. Utilization of solid lipid nanoparticles for enhanced delivery of curcumin in cocultures of HT29-MTX and Caco-2 cells.
Guri A; Gülseren I; Corredig M
Food Funct; 2013 Sep; 4(9):1410-9. PubMed ID: 23921424
[TBL] [Abstract][Full Text] [Related]
2. Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles.
Yuan H; Chen CY; Chai GH; Du YZ; Hu FQ
Mol Pharm; 2013 May; 10(5):1865-73. PubMed ID: 23495754
[TBL] [Abstract][Full Text] [Related]
3. Facilitated nanoscale delivery of insulin across intestinal membrane models.
Woitiski CB; Sarmento B; Carvalho RA; Neufeld RJ; Veiga F
Int J Pharm; 2011 Jun; 412(1-2):123-31. PubMed ID: 21501675
[TBL] [Abstract][Full Text] [Related]
4. A tunable Caco-2/HT29-MTX co-culture model mimicking variable permeabilities of the human intestine obtained by an original seeding procedure.
Béduneau A; Tempesta C; Fimbel S; Pellequer Y; Jannin V; Demarne F; Lamprecht A
Eur J Pharm Biopharm; 2014 Jul; 87(2):290-8. PubMed ID: 24704198
[TBL] [Abstract][Full Text] [Related]
5. Hansen solubility parameters (HSP) for prescreening formulation of solid lipid nanoparticles (SLN): in vitro testing of curcumin-loaded SLN in MCF-7 and BT-474 cell lines.
Doktorovova S; Souto EB; Silva AM
Pharm Dev Technol; 2018 Jan; 23(1):96-105. PubMed ID: 28949267
[TBL] [Abstract][Full Text] [Related]
6. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport.
Hilgendorf C; Spahn-Langguth H; Regårdh CG; Lipka E; Amidon GL; Langguth P
J Pharm Sci; 2000 Jan; 89(1):63-75. PubMed ID: 10664539
[TBL] [Abstract][Full Text] [Related]
7. Interaction of cruciferin-based nanoparticles with Caco-2 cells and Caco-2/HT29-MTX co-cultures.
Akbari A; Lavasanifar A; Wu J
Acta Biomater; 2017 Dec; 64():249-258. PubMed ID: 29030304
[TBL] [Abstract][Full Text] [Related]
8. The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium.
Araújo F; Shrestha N; Shahbazi MA; Fonte P; Mäkilä EM; Salonen JJ; Hirvonen JT; Granja PL; Santos HA; Sarmento B
Biomaterials; 2014 Nov; 35(33):9199-207. PubMed ID: 25109441
[TBL] [Abstract][Full Text] [Related]
9. Solid lipid nanocarriers diffuse effectively through mucus and enter intestinal cells - but where is my peptide?
Dumont C; Beloqui A; Miolane C; Bourgeois S; Préat V; Fessi H; Jannin V
Int J Pharm; 2020 Aug; 586():119581. PubMed ID: 32603838
[TBL] [Abstract][Full Text] [Related]
10. Development of an advanced intestinal in vitro triple culture permeability model to study transport of nanoparticles.
Schimpel C; Teubl B; Absenger M; Meindl C; Fröhlich E; Leitinger G; Zimmer A; Roblegg E
Mol Pharm; 2014 Mar; 11(3):808-18. PubMed ID: 24502507
[TBL] [Abstract][Full Text] [Related]
11. Surface modification of solid lipid nanoparticles for oral delivery of curcumin: Improvement of bioavailability through enhanced cellular uptake, and lymphatic uptake.
Baek JS; Cho CW
Eur J Pharm Biopharm; 2017 Aug; 117():132-140. PubMed ID: 28412471
[TBL] [Abstract][Full Text] [Related]
12. Thiolated eudragit-based nanoparticles for oral insulin delivery: preparation, characterization, and evaluation using intestinal epithelial cells in vitro.
Zhang Y; Du X; Zhang Y; Li G; Cai C; Xu J; Tang X
Macromol Biosci; 2014 Jun; 14(6):842-52. PubMed ID: 24740974
[TBL] [Abstract][Full Text] [Related]
13. HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans.
Walter E; Janich S; Roessler BJ; Hilfinger JM; Amidon GL
J Pharm Sci; 1996 Oct; 85(10):1070-6. PubMed ID: 8897273
[TBL] [Abstract][Full Text] [Related]
14. The formulation and delivery of curcumin with solid lipid nanoparticles for the treatment of on non-small cell lung cancer both in vitro and in vivo.
Wang P; Zhang L; Peng H; Li Y; Xiong J; Xu Z
Mater Sci Eng C Mater Biol Appl; 2013 Dec; 33(8):4802-8. PubMed ID: 24094190
[TBL] [Abstract][Full Text] [Related]
15. Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles.
Silva AC; Kumar A; Wild W; Ferreira D; Santos D; Forbes B
Int J Pharm; 2012 Oct; 436(1-2):798-805. PubMed ID: 22867992
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Caco-2, HT-29 and the mucus-secreting HT29-MTX intestinal cell models to investigate Salmonella adhesion and invasion.
Gagnon M; Zihler Berner A; Chervet N; Chassard C; Lacroix C
J Microbiol Methods; 2013 Sep; 94(3):274-9. PubMed ID: 23835135
[TBL] [Abstract][Full Text] [Related]
17. Intestinal transport of methylmercury and inorganic mercury in various models of Caco-2 and HT29-MTX cells.
Vázquez M; Calatayud M; Vélez D; Devesa V
Toxicology; 2013 Sep; 311(3):147-53. PubMed ID: 23793072
[TBL] [Abstract][Full Text] [Related]
18. Solid lipid nanoparticles for oral drug delivery: chitosan coating improves stability, controlled delivery, mucoadhesion and cellular uptake.
Luo Y; Teng Z; Li Y; Wang Q
Carbohydr Polym; 2015 May; 122():221-9. PubMed ID: 25817662
[TBL] [Abstract][Full Text] [Related]
19. Submicron complex lipid carriers for curcumin delivery to intestinal epithelial cells: Effect of different emulsifiers on bioaccessibility and cell uptake.
Yucel C; Quagliariello V; Iaffaioli RV; Ferrari G; Donsì F
Int J Pharm; 2015 Oct; 494(1):357-69. PubMed ID: 26291881
[TBL] [Abstract][Full Text] [Related]
20. Biorelevant media resistant co-culture model mimicking permeability of human intestine.
Antoine D; Pellequer Y; Tempesta C; Lorscheidt S; Kettel B; Tamaddon L; Jannin V; Demarne F; Lamprecht A; Béduneau A
Int J Pharm; 2015 Mar; 481(1-2):27-36. PubMed ID: 25601199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
